|
 The Swiss company said its Canopy-1 Phase III study did not meet its
primary endpoints when treating patients with previously untreated
locally advanced or metastatic non-small cell lung cancer in
combination with pembrolizumab plus platinum-based doublet
chemotherapy.
The announcement serves as a blow for Novartis after the drug, in
combination with chemotherapy agent docetaxel, failed earlier this
year to improve survival in patients in its Canopy-2 Phase III
study.
Novartis would continue to examine to see whether canakinumab would
be effective both as an after- and pre-surgery treatment, the
company added.
[to top of second column] |
 "CANOPY-1 provides critical
insights into the treatment of this devastating
disease, and we will continue to analyse the
data and conclusions, as well as their potential
clinical implications," John Tsai, Novartis'
head of Global Drug Development and chief
medical officer said.
"While this trial did not confirm the benefit
for all patients we hoped for, we are energized
by the overall CANOPY-1 findings as they support
our commitment to continue studying canakinumab
in lung cancer."
(Reporting by John Revill; Editing by
Christopher Cushing and Sherry Jacob-Phillips)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
